Navigation Links
By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates
Date:6/7/2012

GAITHERSBURG, MD, June 7 As one of the few probiotics with medical food designation for specific illnesses, VSL#3 has been the subject of a collection of more than 80 studies that have demonstrated its use in the dietary management of IBS, ulcerative colitis, and an ileal pouch. Ulcerative colitis patients, in particular, have been shown to benefit from adding VSL#3 medical food to their prescription drug regimen. One particular study shows that the combination of VSL#3 and traditional drug therapy can improve remission rates over drug therapy alone by 10 to 17 percent, and can initiate remission 47 to 69 percent faster. The 8-week study*, conducted in Rome, involved 90 patients who had newly diagnosed or recently relapsed mild-to-moderate UC and compared the effects of the combination of VSL#3 and balsalazine (Colazal), an anti-inflammatory drug commonly prescribed for the treatment of ulcerative colitis, to the use of balsalazine alone and mesalazine (Canasa) alone.

The trial results concluded that the use of low-dose balsalazide and VSL#3 was significantly superior (p<0.02) in obtaining remission than just the use of balsalazide alone (10 percent improvement) and mesalazine alone (17 percent improvement). The VSL#3/balsalazine combination also initiated remission faster than the drug therapy alone with an average of 4 days versus 7.5 days (balsalazide only) and 13 days (mesalazine only). The improvement of well-being and reduction in bowel frequency was significant as well1.

"Many UC patients try a variety of methods in order to extend their time between flare-ups and obtain remission," said Mary Berry, senior product manager at Sigma-Tau Pharmaceuticals, Inc., maker of VSL#3. "By having a personalized regimen with a drug, such as balsalazide, and adding VSL#3 for their dietary management, patients can see a positive and quick remission that will work for them."

Ulcerative colitis is a chronic disease that causes inflammation and sores, called ulcers, in the inner lining of the large intestine, which includes the colon and the rectum. The inflammation causes erosion of the lining of the colon, leading to bleeding, production of pus, diarrhea, and severe abdominal discomfort.

According to Berry, VSL#3 stands apart from other probiotics since it is not a supplement, but a refrigerated medical food that consists of 8 strains of live, freeze-dried lactic acid bacteria. "It is one of the few probiotic preparations supported by Level 1 (double-blind, placebo-controlled) scientific data, and is the only probiotic recognized as an effective tool in the dietary management of ileal pouch by the American College of Gastroenterology1 and by the Cochrane Review2," says Berry.


'/>"/>

Contact: Nicole Egan
negan@rlapr.com
914-241-0086 x28
Robin Leedy & Associates, Inc.
Source:Eurekalert

Related biology news :

1. Invisible helpers: How probiotic bacteria protect against inflammatory bowel diseases
2. Pain relief with PAP injections may last 100 times longer than a traditional acupuncture treatment
3. Some improved cookstoves may emit more pollution than traditional mud cookstoves
4. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
5. Neural stem cell transplants for spinal cord injury maximized by combined, complimentary therapies
6. New discoveries about brain-hand connection sought to improve therapies, treatments, prosthetics
7. Cardio fitness levels of breast cancer patients may affect survival
8. Modest alcohol intake associated with less inflammation in patients with common liver disease
9. Increased fructose consumption may deplete cellular energy in patients with obesity and diabetes
10. New data suggests interferon-free therapy around the corner for HCV patients
11. Drug interactions wont exclude HCV transplant or HIV co-infected patients from treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology: